Luspatercept (2) (Reblozyl®) – Beta thalassemia

1. Characteristics

Start date 01.08.2020
Resolution 21.01.2021
INN Luspatercept
Brand name Reblozyl®
Company Celgene GmbH
G-BA procedure ID 2020-08-01-D-560
ATC code B03XA06
ICD-10 codes D56.1Beta thalassemia
DDD 3.3 mg P
Therapeutic area Hematopoietic diseases ORPHAN
Reason for procedure New indication
Specialties Bundling

Indication (German)

Reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia associated with beta-thalassaemia.

Subgroup Indication Comparator
Erwachsene Patienten mit transfusionsabhängiger Anämie, die mit einer ꞵ-Thalassämie verbunden ist – (Orphan drug)

9. Associated procedures

Resolution INN Brand name Indication Additional benefit
Luspatercept Reblozyl® Myelodysplastic syndrome (MDS)
Luspatercept (2) Reblozyl® Beta thalassemia


<< List of all resolutions